Melanocortin receptor agonist
Melanotan II
Melanotan II after one dose: 50% at ~1 h, 25% at 2 h, 12.5% at 3 h.
Drawn from the half-life in the app's model, ~1 h. The model's figures
- Compound
- Melanotan II
- Symbol
- MT2
- Family
- Cosmetic and copper peptides
- Parts
- 14
- References
- 31
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

3%The 21st most tracked compound in Milligram: of people who track compounds in Milligram logged Melanotan II in the last 90 days.
Schedule
Logged doses
Half of people logged between 100 and 410 mcg per dose; the median was 250 mcg.
Tracked alongside
The share of people logging Melanotan II who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
Melanotan II (MT-II) is described by Dorr and colleagues as a lactam-bridged cyclic heptapeptide with the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha-MSH4-10-NH2.1 Peters and colleagues write that it "is a non-selective melanocortin-receptor agonist" whose effect on humans is "an increasing of skin pigmentation, producing of spontaneous penile erection and sexual stimulation".3 Hadley, of the University of Arizona College of Medicine, wrote in 2005 that its actions on sexual function "were discovered accidentally while studying the effects of the peptide and related analogs on human skin pigmentation (tanning)".4
The TGA states: "There are currently no products containing Melanotan II included in the Australian Register of Therapeutic Goods (ARTG) or approved for supply in Australia".2 In the United States, FDA lists melanotan II in its table "Bulk drug substances nominated but withdrawn" and names it among five substances for an advisory committee meeting "before the end of February 2027".5,6
The app's evidence badge is the app's own grade; the sources describe small trials of 3 to 20 men, a registered phase 2 trial that is recruiting, and case reports of harm.1,7,8,9,10
How it works
Sources in this part
Weirath and Haskell-Luevano wrote in 2024 that there are "five melanocortin receptor subtypes" and that synthetic derivatives of alpha-MSH include "NDP-MSH (melanotan I), melanotan II (MTII), and SHU9119".11 Dorr and colleagues describe melanotan II as having "superpotent melanotropic activity in vitro".1 Hadley wrote that melanotan II "works at the level of the brain".4 In mice given 1 mg/kg intraperitoneally, Hatziieremia and colleagues write that the brain concentrations "confirmed the low penetrability of the peptide in mouse brain".13
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~1 h
- Bioavailability
- 95%
- Typical dose
- 100–500 mcg/day
- Route
- SubQ
- Time to peak
- ~30 min
The figures in the table are the app's own, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 1 hour | No human figure. In rats given 0.3 mg/kg intravenously, plasma levels showed biphasic disposition, and the terminal half-life (t1/2 beta) differed between the two assay methods.14 In mice given 1 mg/kg intraperitoneally, "clearance from plasma was rapid".13 Mallory and colleagues write "we suspect the half-life of MT II is long" without giving a measurement,19 and Hadley and Dorr describe melanotan I and II as two of several "superpotent, prolonged acting, enzymatically resistant" analogs.17 |
| Bioavailability | 95% by subcutaneous injection | No human figure. Lan and colleagues cite "a bioavailability of 4.6% in the rat" (the route is not stated in the summary text).15 |
| Time to peak | About 30 minutes | No figure reported. In 3 men, spontaneous erections were "intermittently experienced for 1-5 hours after MT-II dosing", an effect and not a concentration.1 |
The chart illustrates the app's own half-life and time to peak with the one dosing interval a trial reports; none of the sources cited reports a human concentration curve.1
Level over 1 weeks
Level, as a share of the peak after one 250 mcg dose
As studied: every other day1. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).
An illustration from a pharmacokinetic model using a half-life of 1 hours. It is not a measured level or a suggested dose.
For comparison with a different compound, the label of bremelanotide (Vyleesi) gives a mean terminal half-life of "approximately 2.7 hours" after a single subcutaneous administration; that figure is not a melanotan II measurement.16
Human studies
The four published reports in the table below are from 1996 to 2000, all from groups at the University of Arizona, and enrolled men.1,7 The 2000 review describes the authors' own experience, so its 20 men are not necessarily separate from the men in the other reports.9 A 2026 systematic review of peptides for male sexual dysfunction (12 studies, 372 men) states that "Melanocortin receptor agonists" (in that review, PT-141/bremelanotide and melanotan II) "demonstrated the most consistent improvements in erectile function" and that "Overall, studies were limited by small sample sizes, heterogeneous populations, short follow-up durations, and a lack of comparative studies".18
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Dorr and colleagues, 19961 | Pilot phase I; single-blind, alternating day (saline or MT-II), placebo-controlled | 3 normal male volunteers | Started at 0.01 mg/kg subcutaneously, daily Monday to Friday for 2 consecutive weeks; 2 men escalated to 0.03 mg/kg, 1 to 0.025 mg/kg | Mild nausea at most dose levels; Grade II somnolence and fatigue in 1 of 2 men at 0.03 mg/kg; spontaneous erections for 1 to 5 hours after dosing; increased pigmentation in 2 men. |
| Wessells and colleagues, 19987 | Double-blind, placebo-controlled crossover; erections recorded by RigiScan for 6 hours | 10 men with erectile dysfunction of no known organic cause | 0.025 mg/kg against a vehicle placebo; erections recorded for 6 hours | Clinically apparent erections in 8 of 10 men; mean duration of tip rigidity above 80% was 38.0 minutes with melanotan II and 3.0 with placebo (p=0.0045); nausea, stretching and yawning, and decreased appetite more frequent than with placebo, none requiring treatment. |
| Wessells and colleagues, 2000, Urology8 | Randomized, double-blind, placebo-controlled crossover; RigiScan for 6 hours and a desire questionnaire | 10 men with erectile dysfunction and organic risk factors | 0.025 mg/kg or vehicle, each given twice by subcutaneous injection | Subjectively reported erections after 12 of 19 injections against 1 of 21 placebo doses; mean tip rigidity above 80% lasted 45.3 minutes against 1.9 (P = 0.047); sexual desire higher; 4 of 19 injections followed by severe nausea. |
| Wessells and colleagues, 2000, Int J Impot Res9 | Review of the authors' own double-blind, placebo-controlled crossover experience; RigiScan for 6 hours | 20 men with psychogenic and organic erectile dysfunction | Dose given only for the nausea figure: 0.025 mg/kg | Erection without sexual stimulation in 17 of 20 men; increased desire after 13 of 19 (68%) melanotan II doses against 4 of 21 (19%) placebo doses; 12.9% of subjects had severe nausea at 0.025 mg/kg. |
| Registry record NCT07437560, 202610 | Randomized 1:1, quadruple-masked, placebo-controlled phase 2 study with narrowband UV-B in stable nonsegmental vitiligo; recruiting | Estimated enrollment 60 adults | Melanotan II or placebo plus phototherapy for 24 weeks; dose "administered per protocol" | No results posted; primary outcome is change from baseline in Vitiligo Area Scoring Index total score at 24 weeks; lead sponsor Hudson Biotech (industry); the record calls it an "example trial", lists a single site in Shenzhen, China, and marks it not FDA-regulated. |
Deeper analysis: Dorr and colleagues, Life Sciences, 1996
Dorr and colleagues of the University of Arizona gave 3 normal male volunteers subcutaneous melanotan II or saline on alternating days at a starting dose of 0.01 mg/kg, with two men escalated to 0.03 mg/kg and one to 0.025 mg/kg.1 The authors conclude: "These results demonstrate that MT-II has tanning activity in humans given only 5 low doses every other day by subcutaneous injection", and name 0.025 mg/kg/day as the recommended single dose for future phase I studies.1 Pigmentation increased in 2 of the 3 men, one man at 0.03 mg/kg had Grade II somnolence and fatigue, and the report describes mild nausea at most dose levels and spontaneous erections tied to a stretching and yawning complex.1 The PubMed record lists the research support as "Research Support, U.S. Gov't, P.H.S." and carries no conflict-of-interest statement; the summary text states no limitations, and its own description of the design is a single-blind study of 3 volunteers.1
Deeper analysis: Wessells and colleagues, 1998 and 2000
In the 1998 Journal of Urology crossover study, 8 of 10 men with erectile dysfunction of no known organic cause had clinically apparent erections, and the authors write that melanotan II "has manageable side effects at a dose of 0.025 mg./kg".7 In the 2000 Urology trial of 10 men with organic risk factors, the authors write that "The finding of increased sexual desire warrants further investigation of centrally acting agents on disorders of sexual desire", and report severe nausea after 4 of 19 injections.8 The review of 20 men gives the severe nausea figure as "12.9% of subjects" at 0.025 mg/kg, and its summary text does not state the denominator.9 The PubMed records list research support of the "Research Support, U.S. Gov't, P.H.S." type for the 1998 and 2000 Urology reports, plus "Research Support, Non-U.S. Gov't" for the 2000 Urology report, and carry no conflict-of-interest statement.7,8 Hadley and Dorr, of the University of Arizona College of Medicine, wrote in 2006 that melanotan I and II "have been patented and tested clinically".17
Doses reported in studies
| Source | People | Dose | Length | Result noted |
|---|---|---|---|---|
| Dorr and colleagues, 19961 | 3 men, pilot trial | 0.01 to 0.03 mg/kg subcutaneously | 2 weeks, Monday to Friday, saline and melanotan II on alternating days (5 melanotan II doses) | 0.025 mg/kg/day recommended for future phase I studies. |
| Wessells and colleagues, 1998 and 20007,8 | 10 men and 10 men with erectile dysfunction | 0.025 mg/kg | Erections recorded for 6 hours; 2 injections each of melanotan II and vehicle (2000 trial) | Erections in 8 of 10 men (1998) and after 12 of 19 injections (2000). |
| Nelson and colleagues, 2012, case report12 | 39-year-old man | 6 mg subcutaneously, one injection | Single dose; "six times the recommended starting dose per the patient" | Systemic toxicity and rhabdomyolysis. |
| Mallory and colleagues, 2021, case report19 | 55-year-old man | 2 mg subcutaneously to the abdomen | Single injection | Ischemic priapism of 30 hours. |
| Vadner and Smith, 2026, case report20 | 49-year-old man | 250 mcg, then 500 mcg, then 1000 mcg daily, each level for about 3 days | About 1 week, then melanotan I on a similar schedule | 5 melanomas in situ, with tanning bed use and testosterone use reported. |
Side effects reported
Sources in this part
In the trials, nausea, stretching and yawning, and decreased appetite were reported more often with melanotan II than with placebo (1998), and severe nausea followed 4 of 19 injections (2000), as the studies table shows.7,8 Hadley wrote in 2005 of "minimal or no undesirable side effects", while the trials record severe nausea after some injections.4
Case reports of unregulated use
FDA's page states: "Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism".5 The TGA lists headache, nausea, vomiting, loss of appetite and facial redness as the most common side effects of melanotans, writes that "the most concerning one is the risk of serious skin cancers", and states that "With melanotan-II, there have been reports of increased moles and freckles, kidney dysfunction and swelling of the brain".21
Nelson and colleagues reported a 39-year-old man who injected 6 mg subcutaneously and was seen two hours later with sweating, anxiety, a heart rate of 130 beats per minute that peaked at 146, and diffuse muscle tremors.12 He spent 3 days in intensive care, his urine drug screen was positive for opiates, and the injected substance was confirmed as melanotan II by mass spectrometry.12 Peters and colleagues report a renal infarction "most likely attributed to Melanotan II" and write that a "thrombotic pharmacological influence and possible direct toxic effect on renal parenchyma must be considered"; the authors declare no conflict of interest.3
Mallory and colleagues describe a 55-year-old man with ischemic priapism of 30 hours after a 2 mg subcutaneous injection, who had used melanotan II for over 6 years and needed penoscrotal decompression surgery after bedside treatment failed.19 At 15 weeks he reported new-onset erectile dysfunction with rigidity 4/10 and corpora fibrosis on examination and had no response to PDE5 inhibitors, and the report states there was no concomitant other drug use.19 Dreyer and colleagues report low-flow priapism after an abdominal subcutaneous injection of "melanotan" (the type is not specified in the summary text), with erectile function not recovered at 4 weeks.22
Hjuler and Lorentzen reported a 20-year-old woman with Fitzpatrick skin type II and a melanoma on the gluteal region after a 3- to 4-week course of self-injections with melanotan II, with sunbed use, and the authors note that "the extent and types of adverse effects are unknown".23 Vadner and Smith (2026) report a 49-year-old man with five melanomas in situ who presented after 2 to 3 weeks of melanotan II, then melanotan I, with tanning bed use, and who also reported testosterone use; the authors write that "causality remains unproven" and that the melanomas may have been preexisting.20 Habbema and colleagues, reviewing unregulated use of melanotan I and II in 2017, state that "Four case reports have described melanomas emerging from existing moles either during or shortly after the use of melanotan" while "conclusive evidence linking these phenomena is lacking".24 Bonchev (2026) describes gingival and buccal pigmentation after 64 days of melanotan II injections, with the buccal pigmentation nearly gone at one month and gingival pigmentation persisting at three months.25 The patient had slight gingival pigmentation two years earlier and reported tobacco use and regular sunbed use, and the author writes that the finding "must be interpreted with caution".25
Bloodwork and markers
The app lists no markers to monitor for melanotan II.
Regulatory and anti-doping status
Sources in this part
- 2Therapeutic Goods Administration, 2026
- 5US Food and Drug Administration, 2026
- 6US Food and Drug Administration, 2026
- 16Cosette Pharmaceuticals, 2026
- 21Therapeutic Goods Administration, 2025
- 26US Food and Drug Administration, 2026
- 27US Food and Drug Administration, 2026
- 28Breindahl et al., 2015
- 29Deville et al., 2024
- 30World Anti-Doping Agency, 2026
FDA's page on bulk drug substances that may present significant safety risks, with content current as of 22 April 2026, carries melanotan II in the table headed "Bulk drug substances nominated but withdrawn", a list the page describes as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators", with the statement that compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities".5 FDA's advisory committee page, with content current as of 15 April 2026, says the committee will discuss "Cathelicidin (LL-37) GHK-Cu Dihexa acetate Melanotan II Mechano Growth Factor, Pegylated (PEG-MGF)" for possible inclusion on the 503A bulks list at a meeting before the end of February 2027.6 The text of FDA's list of substances nominated for the 503A bulks list, updated 14 May 2026, contains no entry for melanotan II in its three categories, and the introduction to FDA's briefing for the July 2026 meeting lists seven substance groups that do not include it.26,27 None of the FDA pages and documents cited states why melanotan II is on the committee agenda.5,6,26,27
The TGA states that melanotan II "is a prescription-only medicine in Australia and is not approved for use as a tanning agent".2 It reported that testing of 5 nasal spray bottles labelled "Pure Tans Triple Strength 30 MG" found an estimated 22 mg to 54 mg of melanotan II, based on the labelled volume of 20 mL per bottle.2 In January 2025 the TGA wrote: "Melanotan is not approved for sale or use as a tanning agent in Australia".21
Breindahl and colleagues analysed vials bought from three online shops: the melanotan II content ranged from 4.32 to 8.84 mg although each shop claimed 10 mg, and vials from two shops held unknown impurities of 4.1 to 5.9%, while impurities from the third shop were below the quantification limit.28 Deville and Charlier determined a purity of 30% in a powder from vials labelled "Melanotan II" submitted to a forensic laboratory.29
A related melanocortin receptor agonist, bremelanotide (Vyleesi), carries US approval from 2019 for "premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)", where the low sexual desire "causes marked distress or interpersonal difficulty" and is not due to a co-existing medical or psychiatric condition, problems with the relationship or the effects of a medication or drug substance; the label states that it is not indicated for HSDD in postmenopausal women or in men.16 The WADA 2026 Prohibited List text names no melanotan; its class S0 reads: "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use ... is prohibited at all times".30 The list does not state whether class S0 applies to melanotan II.30
What is not known
The sources cited give no half-life, time to peak, bioavailability or plasma concentration of melanotan II measured in people, so the app's 1 hour, 30 minutes and 95% have no measured human figure beside them. The trials enrolled 3 to 20 men; the 1996 pilot ran 2 weeks, and in the 2000 Urology trial melanotan II and vehicle were each administered twice. The 2026 systematic review of peptides for male sexual dysfunction describes the evidence as limited by "small sample sizes, heterogeneous populations, short follow-up durations, and a lack of comparative studies".18 The registered vitiligo trial has posted no results.10 Case reports describe harm after use of unregulated products, and separate analyses of products sold online (Breindahl and colleagues, the TGA, Deville and Charlier) report contents that differ from labels.24,28,2,29 Vasylieva and colleagues (2026) note that melanotan II and related agents "remain accessible through unregulated markets, raising concerns about product quality, dosing variability, and incompletely characterized adverse effects".31
Frequently asked questions
Sources in this part
- 1Dorr et al., 1996
- 2Therapeutic Goods Administration, 2026
- 3Peters et al., 2020
- 5US Food and Drug Administration, 2026
- 6US Food and Drug Administration, 2026
- 7Wessells et al., 1998
- 8Wessells et al., 2000
- 12Nelson et al., 2012
- 13Hatziieremia et al., 2007
- 16Cosette Pharmaceuticals, 2026
- 17Hadley et al., 2006
- 18Ramez et al., 2026
- 30World Anti-Doping Agency, 2026
What is the half-life of melanotan II?
What is melanotan II?
Is melanotan II approved?
The TGA states that no products containing melanotan II are on the Australian Register of Therapeutic Goods or approved for supply in Australia.2 FDA's page lists melanotan II among substances nominated for compounding and withdrawn, and its advisory committee is to discuss it before the end of February 2027.5,6
Is melanotan II banned by WADA?
The WADA 2026 Prohibited List text does not name melanotan II.30 Its class S0 prohibits at all times any pharmacological substance not addressed elsewhere on the list and with no current approval by any governmental regulatory health authority for human therapeutic use, and the list does not state whether that applies to melanotan II.30
What is the difference between melanotan I and melanotan II?
Nelson and colleagues write that melanotan I "increases melanogenesis and eumelanin content to produce sunless tanning" while melanotan II also produces spontaneous penile erections and sexual stimulation.12
Is melanotan II the same as bremelanotide (PT-141)?
No: Hadley and Dorr describe PT-141 as "A new MTII analog", Ramez and colleagues list "PT-141/bremelanotide and Melanotan II" as the melanocortin receptor agonists they reviewed, and Nelson and colleagues describe bremelanotide as "a variation of Melanotan II".17,18,12 Bremelanotide has US approval from 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) that is not due to a co-existing medical or psychiatric condition, problems with the relationship or the effects of a medication or drug substance, its label states it is not indicated for HSDD in postmenopausal women or in men, and melanotan II has no such approval in the sources cited.16
What side effects have been reported with melanotan II?
In the 1998 trial, nausea, stretching and yawning, and decreased appetite were reported more often than with placebo; in the 2000 Urology trial, nausea and stretching/yawning were, and 4 of 19 injections were followed by severe nausea.7,8 Case reports describe rhabdomyolysis, renal infarction, priapism and melanoma, and FDA lists melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.12,3,5
Guides, tools and comparisons
- Melanotan 2 dosageA guide that answers a question on this compound.
- Calculator for Melanotan IIA calculator set up for this compound.
- Melanotan 1 vs melanotan 2A side-by-side with another compound.
- Previous in Cosmetic and copper peptides: Melanotan IThe compound before this one in the class.
- Next in Cosmetic and copper peptides: PT-141The compound after this one in the class.
References
- Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci 1996. PMID 8637402
- Therapeutic Goods Administration. Melanotan II tanning peptide products found to be inconsistently dosed. Safety advisory, 17 August 2026. TGA safety advisory
- Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep 2020. PMID 31953620
- Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides 2005. PMID 15996790
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Web page, content current as of 22 April 2026. FDA category 2 page
- US Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee. Web page, content current as of 15 April 2026. FDA advisory committee page
- Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol 1998. PMID 9679884
- Wessells H, Gralnek D, Dorr R, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000. PMID 11018622
- Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res 2000. PMID 11035391
- Hudson Biotech. Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo. ClinicalTrials.gov NCT07437560, record verified 2026-11. NCT07437560
- Weirath NA, Haskell-Luevano C. Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs). ACS Pharmacol Transl Sci 2024. PMID 39296259
- Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol 2012. PMID 23121206
- Hatziieremia S, Kostomitsopoulos N, Balafas V, Tamvakopoulos C. A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II. Plasma and brain tissue concentrations following administration in mice. Rapid Commun Mass Spectrom 2007. PMID 17610239
- Ugwu SO, Blanchard J, Nguyen LD, et al. A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats. Biopharm Drug Dispos 1994. PMID 7981427
- Lan EL, Ugwu SO, Blanchard J, et al. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. J Pharm Sci 1994. PMID 7983590
- Cosette Pharmaceuticals, Inc. VYLEESI- bremelanotide injection. DailyMed, published 9 November 2026. DailyMed label
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides 2006. PMID 16412534
- Ramez M, Mostafa MM, Mohamed H, et al. Peptides for male sexual dysfunction: a systematic review of emerging evidence. J Sex Med 2026. PMID 43002584
- Mallory CW, Lopategui DM, Cordon BH. Melanotan Tanning Injection: A Rare Cause of Priapism. Sex Med 2021. PMC7930850
- Vadner DJ, Smith S. Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use. JAAD Case Rep 2026. PMC13279914
- Therapeutic Goods Administration. Don't risk using tanning products containing melanotan. News article, 24 January 2025. TGA news article
- Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep 2019. PMID 30796078
- Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology 2014. PMID 24355990
- Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol 2017. PMID 28266027
- Bonchev A. Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report. Life (Basel) 2026. PMC12942211
- US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. List updated 14 May 2026. FDA 503A categories list
- US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23-24, 2026 (introduction). FDA briefing document
- Breindahl T, Evans-Brown M, Hindersson P, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal 2015. PMID 24771717
- Deville M, Charlier C. Barbie drug identification: Not a child's play. J Forensic Sci 2024. PMID 39302005
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026
- Vasylieva V, West A, Karpman E. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sex Med Rev 2026. PMID 42862021